Biological Therapy in the Management of Recent-Onset Crohn's Disease: Why, When and How?

ISSN： 0012-6667

Source： Drugs, Vol.66, Iss.11, 2006-01, pp. : 1431-1439

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Switching Between Second-Generation Antipsychotics: Why and How?

By Monika Edlinger Susanne Baumgartner Nadja Eltanaihi-Furtmüller Martina Hummer W. Wolfgang Fleischhacker

CNS Drugs, Vol. 19, Iss. 1, 2005-01 ,pp. : 27-42

Adis International

Access to resources Recommend Favorite

Role of Pharmacoeconomic Analysis in R&D Decision Making: When, Where, How?

By Paul Miller

PharmacoEconomics, Vol. 23, Iss. 1, 2005-01 ,pp. : 1-12

Adis International

Access to resources Recommend Favorite

How Important is Onset of Action in Ulcerative Colitis Therapy?

By Masson Steven

Drugs, Vol. 65, Iss. 15, 2005-01 ,pp. : 2069-2083

Adis International

Access to resources Recommend Favorite

Antimycobacterials beneficial in Crohn's disease?

Inpharma, Vol. 1, Iss. 1233, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Monoclonal antibodies for viral infections: where to, and how?

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite